Journal article icon

Journal article

Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: An interview with Adam Mead

Abstract:

Dr Mead earned his medical degree from the University of Oxford and trained in hematology at St Bartholomew's Hospital and University College London. In 2007, he earned his PhD at UCL, which focused on the analysis of FLT3 mutations in acute myeloid leukemia. He is now Associate Professor of Hematology and MRC Senior Clinical Fellow at the WIMM, University of Oxford. His research group focuses on myeloid diseases and normal blood stem-cell biology. Dr Mead is the lead clinician for myeloproli...

Expand abstract
Publication status:
Published
Peer review status:
Reviewed (Other)
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.2217/fon-2017-0460

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM; RDM Clinical Laboratory Sciences
Publisher:
Future Medicine Publisher's website
Journal:
Future Oncology Journal website
Volume:
13
Issue:
27
Publication date:
2017-11-10
Acceptance date:
2017-07-07
DOI:
EISSN:
1744-8301
ISSN:
1479-6694
Pubs id:
pubs:809889
URN:
uri:dbf1be4a-4603-4a88-a726-bfc438f89805
UUID:
uuid:dbf1be4a-4603-4a88-a726-bfc438f89805
Local pid:
pubs:809889

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP